(Q36460838)

14 August 2017

1 reference

title

Clinical pharmacokinetics of ranolazine (English)

1 reference

14 August 2017

1 reference

Markus Jerling

1

1 reference

14 August 2017

1 January 2006

1 reference

Clinical Pharmacokinetics

14 August 2017

1 reference

14 August 2017

45

1 reference

14 August 2017

469-491

1 reference

14 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200645050-00003

14 August 2017

0 references

cites work

Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200645050-00003

Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200645050-00003

Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200645050-00003

Frequency-dependence of myocardial energetics in failing human myocardium as quantified by a new method for the measurement of oxygen consumption in muscle strip preparations

21 January 2018

1 reference

12 December 2020

Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease

1 reference

12 December 2020

Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes

1 reference

12 December 2020

Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein

1 reference

12 December 2020

Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes

1 reference

12 December 2020

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

1 reference

12 December 2020

Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications

1 reference

12 December 2020

Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein

1 reference

12 December 2020

Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina

1 reference

12 December 2020

Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay

1 reference

12 December 2020

In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s

1 reference

12 December 2020

Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris

1 reference

12 December 2020

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors

1 reference

12 December 2020

Toxic digoxin-drug interactions: the major role of renal P-glycoprotein.

1 reference

12 December 2020

Prediction of creatinine clearance from serum creatinine

1 reference

12 December 2020

Transection of the oesophagus for bleeding oesophageal varices

1 reference

12 December 2020

Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem

1 reference

12 December 2020

Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets

1 reference

12 December 2020

The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6.

1 reference

12 December 2020

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties

1 reference

12 December 2020

The influence of age and sex on the clearance of cytochrome P450 3A substrates

1 reference

12 December 2020

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

1 reference

12 December 2020

Human P450 metabolism of warfarin

1 reference

12 December 2020

Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial

1 reference

12 December 2020

The effect of chronic renal failure on hepatic drug metabolism and drug disposition

1 reference

12 December 2020

Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine

1 reference

12 December 2020

Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity

1 reference

12 December 2020

10.2165/00003088-200645050-00003

Identifiers

DOI

1 reference

PubMed ID

16640453

Dimensions Publication ID

14 August 2017

0 references

1 reference

PubMed ID

16640453